Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.

J Immunother Cancer · 2021 · PMC7993344 · PMID 33757987

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, this increase in frequency did not reach statistical significance compared with the pembro+AI cohort (p value 0.07, 3.4% mean increase in palbo+pembro+AI cycle 2 compared with −0.05% decrease in pembro+AI cycle 2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.